Singapore Moves Upstream In The Medtech Value Chain
This article was originally published in Clinica
Executive Summary
Singapore set out to build a knowledge-based economy some 25 years ago and biomedical sciences have been a key focus of successive five-year R&D funding initiatives. In this article exploring Singapore’s R&D landscape – including insights from key decision-makers and innovators – Tina Tan talks to executives of Exploit Technologies Pte Ltd. (ETPL), the commercialization arm of the country’s science and technology agency, A*STAR, on their models for engaging the different players in the innovation ecosystem. She also delves into one of Singapore’s research institutes, the Institute of Bioengineering and Nanotechnology, to find out what academia-industry collaborations are being forged there